Jubilant Pharmova Limited , a leading pharmaceutical company, has announced the resignation of its Chief Financial Officer (CFO) and Whole-Time Director, Arvind Chokhany. The company disclosed this information to the BSE and NSE exchanges as part of its regulatory requirements.

Key Details of the Resignation

Chokhany submitted his resignation letter on July 29, 2025. According to the company's statement, he will continue in his role until the close of business hours on September 30, 2025. This transition period of approximately two months is likely to ensure a smooth handover of responsibilities.

Impact on the Company

The departure of a key executive like the CFO can have significant implications for a company's financial strategy and operations. Jubilant Pharmova has not yet announced a successor, leaving questions about the company's plans for this crucial position.

Company's Performance

While the news of the CFO's resignation is significant, it's worth noting that Jubilant Pharmova has recently reported its financial results for the quarter ended June 30, 2025. The company showed strong performance with the following highlights:

• Consolidated revenue from operations increased by 10% year-over-year to ₹19,007.00 crore.
• EBITDA grew by 14% year-over-year to ₹3,020.00 crore.
• Normalized PAT increased by 48% year-over-year to ₹1,030.00 crore.

Segment Performance

The company's various segments showed mixed results:

Looking Ahead

As Jubilant Pharmova prepares for this leadership transition, stakeholders will be watching closely to see how the company manages the change and who will be appointed to fill this critical role. The strong financial performance in the recent quarter provides a solid foundation for the company as it navigates this transition in its financial leadership.

Jubilant Pharmova Limited , a leading pharmaceutical and life sciences company, has announced its financial results for the first quarter, demonstrating robust growth and improved profitability across most of its business segments.

Revenue Growth and Profitability

The company reported a consolidated revenue from operations of ₹19,007.00 crore for Q1, marking a significant increase of 9.8% compared to ₹17,317.00 crore in the same quarter of the previous year. This growth was driven by strong performances across multiple business segments.

Jubilant Pharmova's profit before tax and exceptional items rose substantially to ₹1,544.00 crore, up from ₹1,038.00 crore in the previous year's Q1, representing a remarkable 48.7% increase. The company's net profit for the quarter stood at ₹1,025.00 crore, showcasing the company's ability to translate revenue growth into bottom-line results.

Segment Performance

The company's diverse portfolio of businesses showed varied performances:

1. Radiopharma: Remained the largest revenue contributor with ₹8,686.00 crore, up 4.4% year-over-year.
2. Contract Development and Manufacturing Organisation (CDMO) - Sterile Injectables: Showed impressive growth, with revenue increasing by 17.5% to ₹3,926.00 crore.
3. Contract Research, Development and Manufacturing Organisation (CRDMO): Demonstrated strong growth with revenue of ₹3,114.00 crore, up 24.9% from the previous year.
4. Allergy Immunotherapy: Reported a 7.4% increase in revenue to ₹1,914.00 crore.
5. Generics: Showed a modest increase of 6.7% in revenue to ₹1,660.00 crore.

Profitability by Segment

The segment-wise profitability before interest and tax showed mixed results:

Balance Sheet and Financial Position

As of the latest quarter-end, Jubilant Pharmova reported total assets of ₹130,033.00 crore, with a significant portion allocated to its key business segments. The company's financial position remains strong, with a paid-up equity share capital of ₹158.00 crore and reserves (excluding revaluation reserves) of ₹62,391.00 crore as of the latest audited balance sheet date.

Management Commentary

Arjun Shanker Bhartia, Joint Managing Director of Jubilant Pharmova Limited, commented on the results, stating, "We are pleased with our performance in Q1, which demonstrates the strength of our diversified business model and our ability to drive growth across multiple segments. The significant improvements in our CDMO and CRDMO businesses are particularly encouraging, and we continue to focus on operational efficiency and innovation to sustain this momentum."

Outlook

While the company has not provided specific guidance for the future, the strong start to the fiscal year positions Jubilant Pharmova well for continued growth. The company's focus on its core pharmaceutical and life sciences businesses, coupled with its robust R&D pipeline and manufacturing capabilities, is expected to drive long-term value creation for shareholders.

Investors and analysts will be watching closely to see if Jubilant Pharmova can maintain this growth trajectory in the coming quarters, particularly in its high-performing segments like CDMO and CRDMO.

Note: All figures are in Indian Rupees (₹) and are based on the consolidated unaudited financial results for the quarter ended, as reported by Jubilant Pharmova Limited.